President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...

This week, the FDA will decide whether to approve Vertex Pharmaceuticals' non-opioid painkiller. Vertex believes pain could ...

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat neurological conditions like Huntington’s.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nanosonics Limited (NNCSF – Research Report) and Eli Lilly ...

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...

The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ...

Intracranial pressure may be just as critical of a factor in the progression of glaucoma as IOP, according to a speaker here ...